Recruiting patients for clinical trials is a major challenge in the CAR T-cell therapy market, as it poses obstacles to the development and approval of new therapies. The CAR T cell therapy market encompasses the segment of the biopharmaceutical industry that focuses on the development, production and commercialization of T cell therapies with chimeric antigen receptors (CARs). CAR T cell therapy companies are developing therapies against several novel targets that have been analyzed in this research report. Given the steady increase in the number of CAR T cell therapies being developed and launched, the CAR T cell therapy market is on track to become one of the most valued markets in the biopharmaceutical industry.
With more than 800 therapy programs in the clinical stages of development, CAR-T cell therapies have already become firmly established in the general pharmaceutical industry. This global market research report on CAR T cell therapies includes an easy-to-search Excel database of all companies that are developing CAR T cell therapies. Some examples of key CAR T cell therapy companies (the full list of companies is available in the full report) include Autolus, Bluebird Bio, Bristol Myers Squibb, Carsgen Therapeutics, Cellectis, Gilead Sciences, Innovative Cellular Therapeutics, Noile-Immune Biotech, Novartis, Shanghai GeneChem, Sinobioway Cell Therapies, Takara Bio and Wellington Zhaotai Therapies. However, the complications and side effects associated with CAR-T cell therapy and the high cost of CAR-T cell therapy hinder market growth. Consequently, the increase in leukemia cases has not only underscored the urgent need for advanced and targeted therapies, but has also positioned CAR T-cell therapy as a transformative and increasingly indispensable component in the ongoing battle against leukemia.
